Journal of the American Society of Cytopathology最新文献

英文中文

Interobserver agreement and diagnostic challenges of Congo red staining for amyloid detection on fat pad aspiration biopsies 用刚果红染色检测脂肪垫抽吸活检组织淀粉样蛋白的观察者间一致性和诊断难题

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.05.003

Introduction

Congo red staining of fat pad fine needle aspiration specimens is a method utilized for evaluation of amyloid deposition. However, these specimens can pose diagnostic challenges for cytopathologists. As part of ongoing internal quality improvement measures, the objective of this study was to evaluate the intradepartmental interobserver agreement of these specimens and to identify factors that affect the variability of the interpretations.

Materials and methods

There were 7 participants, which included 3 trainees, 3 cytopathologists, and 1 cytotechnologist. Each participant reviewed 50 Congo red stained fat pad fine needle aspiration slides. The interpretations were categorized into 3 groups: negative, indeterminate/suspicious, and positive. The participants also noted any interpretation challenges they encountered for each case.

Results

There was only slight interobserver agreement among all participants (κ = 0.133). Stratified by participant group, the interobserver agreement among the trainees was slight bordering on poor (κ = 0.028) and among cytopathologists was fair (κ = 0.249). The highest agreement between 2 observers was between 2 cytopathologists and the level of agreement was moderate bordering on fair (κ = 0.426). There were only 3 cases (6.0%) with full agreement among observers, while in 25 cases (50.0%), there were 2 category differences in interpretations. The primary diagnostic challenge reported by participants was when weak or focal birefringence was encountered as well as cases complicated by poor stain quality and overstaining.

Conclusions

We found only slight interobserver agreement among all study participants. A major area of challenge was cases with weak birefringence resulting in high variance of interpretation among participants.

导言：对脂肪垫细针抽吸标本进行刚果红染色是一种用于评估淀粉样沉积的方法。然而，这些标本可能会给细胞病理学家的诊断带来挑战。作为正在进行的内部质量改进措施的一部分，本研究的目的是评估这些标本的部门内观察者之间的一致性，并确定影响解释变异性的因素。每位参与者审查了 50 张刚果红染色脂肪垫细针穿刺切片。判读结果分为三组：阴性、不确定/可疑和阳性。结果所有参与者的观察者之间只有轻微的一致性（κ = 0.133）。按参与者组别分类，受训者的观察者之间的一致性略差一点（κ = 0.028），细胞病理学家之间的一致性尚可（κ = 0.249）。两名观察者之间的一致性最高的是两名细胞病理学家之间，一致性水平为中度接近一般（κ = 0.426）。只有 3 个病例（6.0%）的观察者意见完全一致，而在 25 个病例（50.0%）中，观察者的解释存在两类差异。参与者报告的主要诊断难题是遇到弱双折射或局灶性双折射，以及因染色质量差和过度染色而复杂化的病例。主要的挑战在于双折射较弱的病例，导致参与者之间的解释差异很大。

{"title":"Interobserver agreement and diagnostic challenges of Congo red staining for amyloid detection on fat pad aspiration biopsies","authors":"","doi":"10.1016/j.jasc.2024.05.003","DOIUrl":"10.1016/j.jasc.2024.05.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Congo red staining of fat pad fine needle aspiration specimens is a method utilized for evaluation of amyloid deposition. However, these specimens can pose diagnostic challenges for cytopathologists. As part of ongoing internal quality improvement measures, the objective of this study was to evaluate the intradepartmental interobserver agreement of these specimens and to identify factors that affect the variability of the interpretations.</p></div><div><h3>Materials and methods</h3><p>There were 7 participants, which included 3 trainees, 3 cytopathologists, and 1 cytotechnologist. Each participant reviewed 50 Congo red stained fat pad fine needle aspiration slides. The interpretations were categorized into 3 groups: negative, indeterminate/suspicious, and positive. The participants also noted any interpretation challenges they encountered for each case.</p></div><div><h3>Results</h3><p>There was only slight interobserver agreement among all participants (κ = 0.133). Stratified by participant group, the interobserver agreement among the trainees was slight bordering on poor (κ = 0.028) and among cytopathologists was fair (κ = 0.249). The highest agreement between 2 observers was between 2 cytopathologists and the level of agreement was moderate bordering on fair (κ = 0.426). There were only 3 cases (6.0%) with full agreement among observers, while in 25 cases (50.0%), there were 2 category differences in interpretations. The primary diagnostic challenge reported by participants was when weak or focal birefringence was encountered as well as cases complicated by poor stain quality and overstaining.</p></div><div><h3>Conclusions</h3><p>We found only slight interobserver agreement among all study participants. A major area of challenge was cases with weak birefringence resulting in high variance of interpretation among participants.</p></div>","PeriodicalId":38262,"journal":{"name":"Journal of the American Society of Cytopathology","volume":"13 5","pages":"Pages 359-366"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141413646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Filtered Lung Specimens Imaged with Proprietary Label-Free Imaging Platform for ROSE 利用 ROSE 专有的无标签成像平台对过滤后的肺部标本进行成像

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.093

Gabriela Oprea-Ilies MD

引用次数: 0

Cytology-Histology Correlation of Lung EBUS FNA with the WHO Reporting System for Lung Cytopathology: An Institutional Experience 肺部 EBUS FNA 与世界卫生组织肺部细胞病理学报告系统的细胞学-组织学相关性：机构经验

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.088

Henrietta Maku MD, PhD, Renee Eng MD, Paul Christensen MD, Michael Thrall MD, Dina Mody MD, Vijayalakshmi Padmanabhan MBBS, MD, MPH

引用次数: 0

Application of Afirma Gene Sequencing Classifier in assessment of Cytologically Indeterminate Thyroid Nodules: A Middle Eastern Population Study 应用 Afirma 基因测序分类器评估细胞学不确定甲状腺结节：一项中东人口研究

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.080

Yasin Ahmed MD , Naail Mohammed Ghazi MD

引用次数: 0

Assessing The Paris System for Reporting Urine Cytopathology- A Year Long Evaluation with Histopathology and NMP 22 Correlation in Atypical Cases 评估用于报告尿液细胞病理学的巴黎系统--利用组织病理学和 NMP 22 对非典型病例的相关性进行的长达一年的评估

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.029

Bandita Das MD , Aseema Das MD , Simanta Jyoti Nath MS, Mch , Sanghamitra Mukherjee , Sudipta Das MD

引用次数: 0

Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity 修改后的甲状腺抽吸术贝塞斯达标准在不降低灵敏度的情况下大大降低了非诊断率。

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.04.005

Introduction

Previous studies suggest that the adequacy rate of thyroid aspirates can be improved by altering the adequacy criteria of the Bethesda System. We sought to measure the performance of these altered criteria in a prospective fashion.

Materials and methods

Over a 6-year period, cases with 1 to 59 follicular cells were prospectively classified as “nondiagnostic, favor benign” or “scant but adequate”. “Scant but adequate” cases were classified as either benign (Bethesda category 2) or atypia of undetermined significance (AUS) (Bethesda category 3). Bethesda category 3 cases were referred for Afirma testing (Veracyte, San Francisco, CA).

Results

Of 5147 cases, 131 (3%) were classified as “nondiagnostic, favor benign”; 45 (65%) of these had follow-up with a risk of malignancy of 2.6%. Additionally, 436 (8%) of all 5147 cases were classified as “scant but adequate” and “benign”; 49 (11%) of these had follow-up with a risk of malignancy of 0%. Lastly, 197 (4%) of all 5147 cases were classified as “scant but adequate” with AUS; 177 (90%) of these 197 cases had an adequate Afirma result. The “suspicious” rate was not significantly different than that of cases classified as “adequate” and AUS (Bethesda category 3 and 4) (35 of 197 [18%] versus 140 of 848 [17%] P = 0.67), and there was no significant difference in the risk of malignancy for these 2 categories (“scant but adequate” 9 of 18, “adequate” 50% versus 27 of 85, 32%, P = 0.10). Overall, the modified Bethesda criteria reduced the nondiagnostic rate from 22% to 10% (P <0.001) without lowering the sensitivity of the test.

Conclusions

Modified Bethesda adequacy criteria can significantly lower nondiagnostic rates without lowering sensitivity.

引言以前的研究表明，通过改变贝塞斯达系统的充分性标准可以提高甲状腺穿刺的充分率。我们试图以前瞻性的方式衡量这些改变后的标准的效果：在6年的时间里，有1到59个滤泡细胞的病例被前瞻性地归类为 "无诊断性、良性 "或 "稀少但足够"。"稀少但充分 "的病例被归类为良性（贝塞斯达分类 2）或意义未定的不典型性（AUS）（贝塞斯达分类 3）。贝塞斯达第 3 类病例被转介进行 Afirma 检测（Veracyte，加利福尼亚州旧金山）：在 5147 例病例中，131 例（3%）被归类为 "无诊断意义，倾向良性"；其中 45 例（65%）进行了随访，恶性风险为 2.6%。此外，在所有 5147 例病例中，有 436 例（8%）被归类为 "稀少但足够 "和 "良性"；其中 49 例（11%）进行了随访，恶变风险为 0%。最后，在所有 5147 例病例中，有 197 例（4%）的 AUS 被归类为 "稀少但足够"；在这 197 例病例中，有 177 例（90%）的 Afirma 结果足够。可疑 "率与归类为 "充分 "和 AUS 的病例（贝塞斯达第 3 和第 4 类）（197 例中的 35 例[18%]与 848 例中的 140 例[17%]相比，P = 0.67）无显著差异，这两类病例的恶性肿瘤风险也无显著差异（"稀少但充分 "18 例中的 9 例，"充分 "50% 与 85 例中的 27 例，32% 相比，P = 0.10）。总体而言，修改后的贝塞斯达标准将非诊断率从 22% 降至 10%（P 结论："修改后的贝塞斯达标准将非诊断率从 22% 降至 10%"）：修改后的贝塞斯达充分性标准可在不降低灵敏度的情况下显著降低非诊断率。

{"title":"Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity","authors":"","doi":"10.1016/j.jasc.2024.04.005","DOIUrl":"10.1016/j.jasc.2024.04.005","url":null,"abstract":"<div><h3>Introduction</h3><p><span>Previous studies suggest that the adequacy rate of thyroid aspirates can be improved by altering the adequacy criteria of the </span>Bethesda System. We sought to measure the performance of these altered criteria in a prospective fashion.</p></div><div><h3>Materials and methods</h3><p>Over a 6-year period, cases with 1 to 59 follicular cells were prospectively classified as “nondiagnostic, favor benign” or “scant but adequate”. “Scant but adequate” cases were classified as either benign (Bethesda category 2) or atypia of undetermined significance (AUS) (Bethesda category 3). Bethesda category 3 cases were referred for Afirma testing (Veracyte, San Francisco, CA).</p></div><div><h3>Results</h3><p><span>Of 5147 cases, 131 (3%) were classified as “nondiagnostic, favor benign”; 45 (65%) of these had follow-up with a risk of malignancy of 2.6%. Additionally, 436 (8%) of all 5147 cases were classified as “scant but adequate” and “benign”; 49 (11%) of these had follow-up with a risk of malignancy of 0%. Lastly, 197 (4%) of all 5147 cases were classified as “scant but adequate” with AUS; 177 (90%) of these 197 cases had an adequate Afirma result. The “suspicious” rate was not significantly different than that of cases classified as “adequate” and AUS (Bethesda category 3 and 4) (35 of 197 [18%] versus 140 of 848 [17%] </span><em>P</em> = 0.67), and there was no significant difference in the risk of malignancy for these 2 categories (“scant but adequate” 9 of 18, “adequate” 50% versus 27 of 85, 32%, <em>P</em> = 0.10). Overall, the modified Bethesda criteria reduced the nondiagnostic rate from 22% to 10% (<em>P</em> <0.001) without lowering the sensitivity of the test.</p></div><div><h3>Conclusions</h3><p>Modified Bethesda adequacy criteria can significantly lower nondiagnostic rates without lowering sensitivity.</p></div>","PeriodicalId":38262,"journal":{"name":"Journal of the American Society of Cytopathology","volume":"13 5","pages":"Pages 346-349"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reclassification of Thyroid Neoplasms with Aid of Genetic Alterations and Their Surrogate Markers 借助遗传变异及其替代标志物对甲状腺肿瘤进行重新分类

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.083

Ali Mokhtari MD , Daniel Lubin MD , Xiaoqi Lin MD, PhD , Kartik Viswanathan MD PhD , Dehong Li , Di Ai MD, PhD , Qiuying Shi MD

引用次数: 0

Cytomorphological Features for Fine Needle Aspiration of Thyroid Nodules Post Radioactive Iodine Treatment 放射性碘治疗后甲状腺结节细针抽吸的细胞形态学特征

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.008

Rong Xia MD, PhD, Insoo Suh MD, Sruthi Ramesh BS, Fang Zhou MD, Cheng Liu MD, Brendan Belovarac MD, Kepal Patel MD, Aylin Simsir MD, Wei Sun MD

引用次数: 0

The Impact of Robotic Assistance-Based Navigation Systems on the Adequacy of EBUS-Guided Cytology Specimens - Experience From a Large University Hospital 基于机器人辅助的导航系统对 EBUS 引导的细胞学标本充分性的影响 - 一家大型大学医院的经验

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.087

Poorva Singh MD, MBA, DipRCPath, Mohammad Alutaibi MBBS, David Cartwright MD, Khalid Amin MD, Jimmie Stewart MD

引用次数: 0

Pericardial Fluid Cytology: Insights from a Five-Year Retrospective Review 心包积液细胞学：五年回顾性研究的启示

Q2 Medicine

Journal of the American Society of Cytopathology

Pub Date : 2024-09-01 DOI: 10.1016/j.jasc.2024.08.035

Dina Zenezan MD, Nikolina Dioufa MD, PhD, Kassaye Firde MD, Israh Akhtar MD, FIAC

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of the American Society of Cytopathology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀